SignalFDA/Bio
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TO
FDA Type C meeting success supports potential accelerated and full approval for IDE849 in neuroendocrine carcinomas.
Context
What happened: IDEAYA Biosciences said a US FDA Type C meeting supported registrational trial designs for IDE849 in neuroendocrine carcinomas, including a single-arm cohort for potential accelerated approval and a randomized Phase 3 for full approval.
Key numbers: Single-arm cohort about 90 refractory GEP-NEC patients; ORR 52.6% (10/19), median PFS 7.0 months, 9-month OS rate 82.4% in
Why it matters: The company said the ESMO data support the clinical benefit of a DLL3-targeted ADC in NEC, and it aims to position IDE849 in a fast-evolving DLL3 landscape across refractory NEC and ES-SCLC.
Market: -4.6% today ($30.36), -10.3% YTD, 0.6x vol — as of 22:47 UTC
What changed
IDEAYA Biosciences said a US FDA Type C meeting supported registrational trial designs for IDE849 in neuroendocrine carcinomas, including a single-arm cohort for potential accelerated approval and a randomized Phase 3 for full approval.
Why it matters
The company said the ESMO data support the clinical benefit of a DLL3-targeted ADC in NEC, and it aims to position IDE849 in a fast-evolving DLL3 landscape across refractory NEC and ES-SCLC.
Market: -4.6% today ($30.36), -10.3% YTD, 0.6x vol — as of 22:47 UTC